

## NOTIFICATION OF PARTICIPATION AND FORM FOR ADVANCE VOTING

**The form must be received by Infant Bacterial Therapeutics AB (publ) no later than Tuesday, May 3, 2022.**

The shareholder below is hereby notifying the company of its participation and exercising the voting right for all of the shareholder's shares in Infant Bacterial Therapeutics AB (publ), Reg. No. 556873-8586 at the Annual General Meeting on Wednesday, May 4, 2022. The voting right is exercised in accordance with the voting options marked below.

Shareholder	Personal identity number/registration number

**Assurance (if the undersigned is a legal representative of a shareholder who is a legal entity):** I, the undersigned, am a board member, the CEO or a signatory of the shareholder and solemnly declare that I am authorised to submit this advance vote on behalf of the shareholder and that the contents of the advance vote correspond to the shareholder's decisions

**Assurance (if the undersigned represents the shareholder by proxy):** The undersigned solemnly declare that the enclosed power of attorney corresponds to the original and has not been revoked

<b>Place and date</b>	
<b>Signature</b>	
<b>Clarification of signature</b>	
<b>Telephone number</b>	<b>E-mail</b>

**Instructions:**

- Complete all the requested information above
- Select the preferred voting options below
- Print, sign and send the form by post to Infant Bacterial Therapeutics AB (publ), Bryggargatan 10, SE-111 21 Stockholm, Sweden. Completed and signed advance votes may also be submitted electronically to [ibt@ibtherapeutics.com](mailto:ibt@ibtherapeutics.com)
- If the shareholder is a natural person who is personally voting in advance, it is the shareholder who should sign under *Signature* above. If the advance vote is submitted by a proxy of the shareholder, it is the proxy who should sign. If the advance vote is submitted by a legal representative of a legal entity, it is the representative who should sign
- If the shareholder votes by proxy, a proxy shall be enclosed to the form. If the shareholder is a legal entity, a certificate of incorporation or an equivalent certificate of authority should be enclosed to the form

**A shareholder whose shares have been registered in the name of a bank or securities institute must register its shares in its own name to vote.** Instructions for this is included in the notice convening the General Meeting.

A shareholder cannot give any other instructions than selecting one of the options specified at each point in the form. If a shareholder wishes to abstain from voting in relation to a matter, kindly refrain from selecting an option. A vote (*i.e.* the advance voting in its entirety) is invalid if the shareholder has provided the form with specific instructions or conditions or if pre-printed text is amended or supplemented.

The advance voting form, together with any enclosed authorisation documentation, shall be provided to Infant Bacterial Therapeutics AB (publ) no later than Tuesday, May 3, 2022. An advance vote can be withdrawn up to and including Tuesday, May 3, 2022 by contacting Infant Bacterial Therapeutics AB (publ) via e-mail to [ibt@ibtherapeutics.com](mailto:ibt@ibtherapeutics.com) or by post to Infant Bacterial Therapeutics AB (publ), Bryggargatan 10, SE-111 21 Stockholm, Sweden.

One form per shareholder will be considered. If more than one form is submitted, the form with the latest date will be considered. The form latest received by Infant Bacterial Therapeutics AB (publ) will be considered if two forms are dated at the same date. An incomplete or wrongfully completed form may be discarded without being considered.

For the complete proposals, kindly refer to the notice convening the General Meeting and the company's website.

For information on how your personal data is processed, see the integrity policy that is available at Euroclear's website, [www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf](http://www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf).

## Annual General Meeting in Infant Bacterial Therapeutics on May 4, 2022

The options below comprise the submitted proposals included in the notice convening the Annual General Meeting and are held available on the company's website.

<b>1. Election of Chairman of the Meeting</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>2. Election of one or two persons to approve the minutes of the Meeting</b>
2.1. Jannis Kitsakis or, to the extent he is prevented, the person assigned by the Nomination Committee Yes <input type="checkbox"/> No <input type="checkbox"/>
2.2 Sten Irwe or, to the extent he is prevented, the person assigned by the Nomination Committee Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>3. Establishment and approval of the voting list</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>4. Approval of agenda</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>5. Resolution as to whether the Meeting has been duly convened</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>6. Presentation of the annual report and the audit report, the consolidated accounts and the consolidated audit report</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>7a. Decision to determine the income statement and balance sheet and the consolidated income statement and consolidated balance sheet</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>7b. Decision on disposals of the company's income according to the established balance sheet</b> Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>7c. Decision on discharge from liability for the Board members and the managing director</b>
1. Peter Rothschild Yes <input type="checkbox"/> No <input type="checkbox"/>
2. Margareta Hagman Yes <input type="checkbox"/> No <input type="checkbox"/>
3. Anthon Jahreskog Yes <input type="checkbox"/> No <input type="checkbox"/>

4. Robert Molander Yes <input type="checkbox"/> No <input type="checkbox"/>
5. Eva Idén Yes <input type="checkbox"/> No <input type="checkbox"/>
6. Kristina Sjöblom Nygren Yes <input type="checkbox"/> No <input type="checkbox"/>
7. Staffan Strömberg Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>8. Resolution regarding the number of Board members and Auditors</b>
8.1 Number of Board members Yes <input type="checkbox"/> No <input type="checkbox"/>
8.2 Number of Auditors Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>9. Determinations of fees to the Board of Directors and Auditor</b>
9.1 Fees to the Board of Directors Yes <input type="checkbox"/> No <input type="checkbox"/>
9.2 Fees to the Remuneration Committee for the time from the previous Annual General Meeting Yes <input type="checkbox"/> No <input type="checkbox"/>
9.3 Fees to the Auditors Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>10. Election of Board members</b>
a. Re-election of Margareta Hagman as board member Yes <input type="checkbox"/> No <input type="checkbox"/>
b. Re-election of Eva Idén as board member Yes <input type="checkbox"/> No <input type="checkbox"/>
c. Re-election of Anthon Jahreskog as board member Yes <input type="checkbox"/> No <input type="checkbox"/>
d. Re-election of Kristina Sjöblom Nygren as board member Yes <input type="checkbox"/> No <input type="checkbox"/>
e. Re-election of Peter Rothschild as board member Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>11. Election of the Chairman of the Board</b>

Re-election of Peter Rothschild as Chairman of the Board Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>12. Election of Auditor</b>
Re-election of Deloitte AB Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>13. Resolution regarding the Nominating Committee</b>
Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>14. Presentation of the Board's remuneration report for approval</b>
Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>15. The Board's proposal for a resolution regarding principles for remuneration to senior executives</b>
Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>16. The Board's proposal for resolution regarding authorization for new issuance of shares</b>
Yes <input type="checkbox"/> No <input type="checkbox"/>
<b>17. The Board's proposal for a resolution regarding implementation of an incentive program</b>
Yes <input type="checkbox"/> No <input type="checkbox"/>

<p><b>The shareholder wishes that the resolutions under one or several items in the form above be deferred to a continued general meeting</b></p> <p>(Completed only if the shareholder has such a wish)</p> <p>Item/items (use numbering):</p>
---